Department of Diagnostic and Interventional Radiology, Eberhard-Karls-University, Hoppe-Seyler-Str. 3, 72076 Tübingen, Germany.
AJR Am J Roentgenol. 2010 Jan;194(1):5-14. doi: 10.2214/AJR.09.2744.
The purpose of this article is to illustrate the characteristic changes induced in different tumor types by the multitargeted tyrosine kinase inhibitor sorafenib.
Sorafenib reduces tumor perfusion and thereby induces necrosis and often hemorrhage. Malignant tumors treated with sorafenib undergo both morphologic and functional changes; however, the morphologic changes are less frequent and inadequate for early evaluation of response. Therefore, imaging tools accurately assessing hemorrhage and decrease in tumor perfusion with subsequent necrosis should be the mainstay in monitoring targeted therapy agents.
本文旨在阐述多靶点酪氨酸激酶抑制剂索拉非尼诱导不同肿瘤类型的特征性变化。
索拉非尼可降低肿瘤灌注，从而诱导坏死并常引起出血。接受索拉非尼治疗的恶性肿瘤会发生形态和功能变化；然而，形态变化不常见且不足以进行早期疗效评估。因此，准确评估出血和肿瘤灌注减少继而引起坏死的影像学工具应成为监测靶向治疗药物的主要手段。
